A case report shows naltrexone may reduce opioid overdose risk in stimulant use disorder, suggesting a new harm-reduction strategy.
Oral naltrexone may represent a novel harm-reduction intervention to mitigate opioid-related morbidity and mortality in the setting of an increasingly adulterated stimulant supply. Further research is needed to evaluate efficacy and implementation.
No takes yet. Share an insight, caveat, or question.
Jaffe et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: